Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL

January 28th, 2019 by Christian Schmidl

Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL

Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL, Published online: 28 January 2019; doi:10.1038/s41589-018-0205-2

Epigenome profiling in combination with imaging-based chemosensitivity and integrative bioinformatic analysis establishes a method for detecting therapy-induced vulnerabilities, as shown here for ibrutinib-treated chronic lymphocytic leukemia.
  • Posted in Nat Chem Biol, Publications
  • Comments Off on Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL